PAX6 and gastric cancer: Finally, the hypermethylation of PAX6 was observed to correlate with poor clinical outcome in gastric cancer [25, 26], development of non-small cell lung cancer [27] and transcriptional deactivation in invasive ductal breast carcinoma [28, 29].